The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. RESULTS: During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib). CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
In the citing paper
“both the rarity of co-drivers and strong addiction to the ALK fusion oncoprotein may account for the long progression-free survival observed in patients with ALK-rearrangements with the potent and selective second and third generation ALK inhibitors alectinib, brigatinib and lorlatinib23, 26, 27.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citationGainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A., West, H., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 709
Self-citationShaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citationOu, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 592
Self-citationBrain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 265
Self-citationALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 245
Self-citation
Research works printed but not linked: 3
- Awad MM, 2014, Clin Adv Hematol Oncol, 12, 429
- Lu S, 2016, J Clin Oncol
- Hida T, Lancet
Cited by
Sorted by citations
Items 501–600 of 1,000
Shokoohi, A., Al-Hashami, Z. S., Moore, S. M., Pender, A., Wong, S. K., Wang, Y., Leung, B. O., Wu, J., & Ho, C. (2021) · Cancer Medicine · doi:10.1002/cam4.4427 · Cited by 34
Aizer, A. A., & Lee, E. Q. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.010 · Cited by 34
Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC
Lara‐Mejía, L., Cardona, A. F., Mas, L. A., Martin, C. M., Samtani, S., Corrales, L., Cruz‐Rico, G., Remón, J., Gálvez-Niño, M., Ruiz, R., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.007 · Cited by 33
Self-citationPiggott, L. M., Hayes, C., Greene, J., & Fitzgerald, D. B. (2023) · Breathe · doi:10.1183/20734735.0145-2023 · Cited by 33
Lee, S., Menis, J., Kim, T. M., Kim, H. R., Zhou, C., Kurniawati, S., Prabhash, K., Hayashi, H., Lee, D. D.-W., Imasa, M. S. B., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103996 · Cited by 33
Self-citationMuller, I. B., Langen, A. J. D., Giovannetti, E., & Peters, G. J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s109493 · Cited by 34
Spagnuolo, A., Maione, P., & Gridelli, C. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1527902 · Cited by 33
Uchida, A., Seki, N., Mizuno, K., Misono, S., Yamada, Y., Kikkawa, N., Sanada, H., Kumamoto, T., Suetsugu, T., & Inoue, H. (2018) · Cancer Science · doi:10.1111/cas.13853 · Cited by 34
Update on emerging biomarkers in lung cancer
Bernicker, E., Allen, T. C., & Cagle, P. T. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.01.46 · Cited by 33
Pirker, R., & Filipits, M. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000548 · Cited by 33
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma
Hillier, K., Hughes, A. L., Shamberger, R. C., Shusterman, S., Pérez‐Atayde, A. R., Wassner, A. J., Iafrate, A. J., Dubuc, A. M., Janeway, K. A., Rothenberg, S. M., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0041 · Cited by 33
Hoang, T., Myung, S., Pham, T. T., & Park, B. (2020) · Cancers · doi:10.3390/cancers12030526 · Cited by 35
Singh, H., Li, Y. Y., Spurr, L. F., Shinagare, A. B., Abhyankar, R., Reilly, E., Brais, L. K., Nag, A., Ducar, M. D., Thorner, A. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4073 · Cited by 33
Nagasaka, M., & Ou, S. I. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.021 · Cited by 33
Self-citationChoudhury, N. J., Schneider, J. L., Patil, T., Zhu, V. W., Goldman, D. A., Yang, S., Falcon, C. J., Do, A., Nie, Y., Plodkowski, A. J., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100187 · Cited by 33
Self-citationStein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 33
Xiong, Q., Qin, B., Xin, L., Yang, B. Y., Song, Q., Wang, Y., Zhang, S., & Hu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659380 · Cited by 33
van Veelen, A., van Geel, R. M. J. M., Schoufs, R., de Beer, Y. M., Stolk, L. M., Hendriks, L. E. L., & Croes, S. (2021) · Biomedical Chromatography · doi:10.1002/bmc.5224 · Cited by 34
Shi, Y., Fang, J., Hao, X., Zhang, S., Liu, Y., Wang, L., Chen, J., Hu, Y., Hang, X., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00841-8 · Cited by 34
Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management
Nakano, T., Tanimura, K., Uchino, J., Kaneko, Y., Tamiya, N., Yamada, T., & Takayama, K. (2018) · BioMed Research International · doi:10.1155/2018/8202971 · Cited by 35
Makimoto, G., Ohashi, K., Tomida, S., Nishii, K., Matsubara, T., Kayatani, H., Higo, H., Ninomiya, K., Satô, A., Watanabe, H., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.017 · Cited by 33
Durvalumab for the treatment of non-small cell lung cancer
Murakami, S. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1699407 · Cited by 33
Peled, N., Gillis, R., Kılıçkap, S., Froesch, P., Орлов, С. В., Filippova, E., Demırcı, U., Christopoulos, P., Çiçin, İ., Başal, F. B., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.022 · Cited by 34
Self-citationLuo, Y., Zhang, Z., Guo, X., Tang, X., Li, S., Gong, G., Gao, S. L., Zhang, Y., & Lin, S. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107319 · Cited by 33
Negrao, M. V., Paula, A. G., Molkentine, D. P., Hover, L. D., Nilsson, M. B., Vokes, N. I., Engstrom, L. D., Calinisan, A., Briere, D. M., Waters, L. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2310 · Cited by 33
Small-molecule PROTACs: Novel Agents for Cancer Therapy
Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 32
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
Jahanzeb, M., Lin, H. M., Pan, X., Yin, Y., Wu, Y., Nordstrom, B. L., & Socinski, M. A. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0011 · Cited by 33
Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer
Montagna, M. L., GINN, L. H., & Garofalo, M. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00214-3 · Cited by 32
Naito, T., Shiraishi, H., & Fujiwara, Y. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa192 · Cited by 33
Baschnagel, A. M., Kaushik, S., Durmaz, A., Goldstein, S., Ong, I. M., Abel, L., Clark, P. A., Gürel, Z., Leal, T. A. B., Buehler, D. G., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81832-1 · Cited by 32
Molecular Profiles of Brain Metastases: A Focus on Heterogeneity
Ali, S., Górska, Z., Duchnowska, R., & Jassem, J. (2021) · Cancers · doi:10.3390/cancers13112645 · Cited by 33
Andō, K., Manabe, R., Kishino, Y., Kusumoto, S., Yamaoka, T., Tanaka, A., Ohmori, T., & Sagara, H. (2021) · Cancers · doi:10.3390/cancers13153704 · Cited by 33
Ma, H., Liu, Y., Ding, K., Liu, Y., Zhao, W.-J., Zhu, Y.-J., Chang, X., Chen, Y., Xiao, Z., Yu, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08977-0 · Cited by 32
Hua, G., Zhang, X., Zhang, M., Wang, Q., Chen, X., Yu, R., Bao, H., Liu, J., Wu, X., Shao, Y., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100337 · Cited by 32
Dziadziuszko, R., Peters, S., Ruf, T., Cardona, A. F., Guerini, E., Kurtsikidze, N., Smoljanović, V., & Planchard, D. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100612 · Cited by 32
Self-citationReviewing RECIST in the Era of Prolonged and Targeted Therapy
Morgan, R. L., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.015 · Cited by 35
Self-citationPrecision Medicine in Lung Cancer Treatment
Shah, D. R., & Masters, G. A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.002 · Cited by 32
The neuronal receptor tyrosine kinase Alk is a target for longevity
Woodling, N. S., Aleyakpo, B., Dyson, M. C., Minkley, L. J., Rajasingam, A., Dobson, A. J., Leung, K. H. C., Pomposova, S., Fuentealba, M., Alic, N., et al. (2020) · Aging Cell · doi:10.1111/acel.13137 · Cited by 34
Management of Brain Metastases
Collier, E. F., Chiang, V., & Goldberg, S. B. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_6 · Cited by 32
Ao, Y.-Q., Gao, J., Jin, C., Wang, S., Zhang, L., Deng, J., Chen, Z.-W., Wang, H., Jiang, J.-H., & Ding, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007766 · Cited by 31
Peters, S., Camidge, D. R., Dziadziuszko, R., Gadgeel, S. M., Shaw, A. T., Kim, D., Pérol, M., Rosell, R., Cheema, P. K., Lim, D. W.-T., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.09.018 · Cited by 31
Self-citationTreatment of ALK-positive nonsmall cell lung cancer: recent advances
Thai, A. A., & Solomon, B. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000431 · Cited by 32
Oncogene-addicted non-small cell lung cancer and immunotherapy
Tsakonas, G., & Ekman, S. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.82 · Cited by 31
New developments in brain metastases
Berghoff, A. S., & Preusser, M. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418785502 · Cited by 31
Zhang, Z., Guo, H., Lu, Y., Hao, W., & Han, L. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.03.76 · Cited by 31
Hyman, D. M., Tran, B., Paz-Ares, L. G., Machiels, J.-P., Schellens, J. H. M., Bedard, P. L., Campone, M., Cassier, P. A., Sarantopoulos, J., Vaishampayan, U. N., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00221 · Cited by 31
Arai, S., Takeuchi, S., Fukuda, K., Taniguchi, H., Nishiyama, A., Tanimoto, A., Satouchi, M., Yamashita, K., Ohtsubo, K., Nanjo, S., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.001 · Cited by 31
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis
Cirne, F., Zhou, S., Kappel, C., El-Kadi, A., Barron, C. C., Ellis, P. M., Sanger, S., & Leong, D. P. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.014 · Cited by 31
Lee, J., & Ahn, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102291 · Cited by 31
Peng, L., Lu, D., Xia, Y., Hong, S., Selvaggi, G., Stebbing, J., Sun, Y., & Liang, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754768 · Cited by 31
Morcos, P. N., Nueesch, E., Jaminion, F., Guerini, E., Hsu, J., Bordogna, W., Balas, B. I., & Mercier, F. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3597-5 · Cited by 32
Self-citationStrategies to Preserve Cognition in Patients With Brain Metastases: A Review
Robin, T. P., & Rusthoven, C. G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00415 · Cited by 31
Ou, S. I., Gadgeel, S. M., Barlési, F., Yang, J. C., Petris, L. D., Kim, D., Govindan, R., Dingemans, A. C., Crinò, L., Léna, H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.015 · Cited by 31
Self-citationFrom Genomics to AI: Revolutionizing Precision Medicine in Oncology
Calvino, G., Farro, J., Zampatti, S., Peconi, C., Megalizzi, D., Trastulli, G., Andreucci, S., Cascella, R., Strafella, C., Caltagirone, C., et al. (2025) · Applied Sciences · doi:10.3390/app15126578 · Cited by 30
Treating ALK-positive non-small cell lung cancer
Ziogas, D. C., Tsiara, A., Tsironis, G., Lykka, M., Liontos, M., Bamias, A., & Dimopoulos, M. A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.34 · Cited by 30
Breadner, D. A., Blanchette, P., Shanmuganathan, S., Boldt, G., & Raphael, J. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.011 · Cited by 30
Madison, R. W., Schrock, A. B., Castellanos, E. H., Gregg, J. P., Snider, J. W., Ali, S. M., Miller, V. A., Singal, G., Alexander, B. M., Venstrom, J. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.033 · Cited by 30
Britschgi, C., Addeo, A., Rechsteiner, M., Delaloye, R., Früh, M., Metro, G., Banini, M., Gautschi, O. P., Rothschild, S. I., Wild, P. J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01299 · Cited by 31
Tan, K., Bryan, J., Segal, B. D., Bellomo, L. P., Nussbaum, N., Tucker, M., Torres, A. Z., Bennette, C., Capra, W. B., Curtis, M. D., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2351 · Cited by 32
A Comprehensive Understanding of Choroidal Metastasis from Lung Cancer
Qu, Z., Liu, J., Zhu, L., & Zhou, Q. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s315532 · Cited by 30
Fukui, T., TACHIHARA, M. Y., Nagano, T., & Kobayashi, K. (2022) · Cancers · doi:10.3390/cancers14051184 · Cited by 31
García-Pardo, M., Chang, A., Schmid, S., Dong, M., Brown, M. C., Christiani, D. C., Tindel, H. A., Brennan, P., Chen, C., Zhang, J., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.020 · Cited by 30
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
Huffman, B. M., Ellis, H., Jordan, A. C., Freed-Pastor, W. A., Perez, K. J., Rubinson, D. A., Sethi, N. S., Singh, H., Surana, R., Wolpin, B. M., et al. (2022) · Cancers · doi:10.3390/cancers14246223 · Cited by 31
Kato, K., Okami, J., Nakamura, H., Honma, K., Sato, Y., Nakamura, S., Kukita, Y., Nakatsuka, S., & Higashiyama, M. (2023) · Diagnostics · doi:10.3390/diagnostics13081476 · Cited by 30
Leszek, P., Klotzka, A., Bartuś, S., Burchardt, P., Czarnecka, A. M., Długosz‐Danecka, M., Gierlotka, M. J., Koseła-Paterczyk, H., Krawczyk‐Ożóg, A., Kubiatowski, T., et al. (2023) · Kardiologia Polska · doi:10.33963/v.kp.96840 · Cited by 31
Nardone, V., Nanni, S., Pastina, P., Vinciguerra, C., Cerase, A., Correale, P., Guida, C., Giordano, A., Tini, P., Reginelli, A., et al. (2019) · Strahlentherapie und Onkologie · doi:10.1007/s00066-019-01475-0 · Cited by 30
Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
Vilachã, J. F., Mitchel, S. C., Akele, M. Z., Evans, S., & Groves, M. R. (2020) · Crystals · doi:10.3390/cryst10090725 · Cited by 29
Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
Kalvapudi, S., Vedire, Y., Yendamuri, S., & Barbi, J. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1286104 · Cited by 30
Cancer brain metastasis: molecular mechanisms and therapeutic strategies
Lu, Y., Huang, Y., Zhu, C., Li, Z., Zhang, B., Sheng, H., Li, H., Liu, X., Xu, Z., Wen, Y., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00251-0 · Cited by 29
ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients
Hofman, P. M. (2017) · Cancers · doi:10.3390/cancers9080106 · Cited by 29
Jiang, J., Wu, X., Tong, X., Wei, W., Chen, A., Wang, X., Shao, Y. W., & Huang, J. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.10.011 · Cited by 29
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment
Zaman, A., & Bivona, T. G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.02 · Cited by 29
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080192 · Cited by 29
Descourt, R., Pérol, M., Rousseau-Bussac, G., Planchard, D., Mennecier, B., Wislez, M., Cortot, A. B., Guisier, F., Galland, L., Dô, P., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.010 · Cited by 30
Zhang, C., Yan, L., Jiang, B., Wu, Y.-L. L. C., & Zhong, W. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.133 · Cited by 29
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Tabbò, F., Reale, M. L., Bironzo, P., & Scagliotti, G. V. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-372 · Cited by 29
Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
Kauffmann-Guerrero, D. E., Kahnert, K., & Huber, R. M. (2020) · Drugs · doi:10.1007/s40265-020-01445-2 · Cited by 29
Smolle, E., Taucher, V., Lindenmann, J., Jost, P. J., & Pichler, M. (2021) · Cancers · doi:10.3390/cancers13040699 · Cited by 29
Angeli, E., & Bousquet, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091446 · Cited by 30
Wang, B., Guo, H., Xu, H., Yu, H., Chen, Y., & Zhao, G. (2021) · Cells · doi:10.3390/cells10102620 · Cited by 29
Comparison of sampling methods for next generation sequencing for patients with lung cancer
Kunimasa, K., Matsumoto, S., Nishino, K., Honma, K., Maeda, N., Kuhara, H., Tamiya, M., Inoue, T., Kawamura, T., Kimura, T., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4632 · Cited by 29
Dagogo‐Jack, I., Oxnard, G. R., Evangelist, M. C., Digumarthy, S. R., Lin, J. J., Gainor, J. F., Murphy, J. F., Rabin, M. S., Heist, R. S., Muzikansky, A., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00522 · Cited by 29
Self-citationKim, D., Gadgeel, S. M., Gettinger, S. N., Riely, G. J., Oxnard, G. R., Mekhail, T. M., Schmid, P., Dowlati, A., Heist, R. S., Wozniak, A. J., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100367 · Cited by 29
Self-citationNon-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
Marinelli, D., Siringo, M., Metro, G., Ricciuti, B., & Gelibter, A. J. (2022) · Drugs in Context · doi:10.7573/dic.2022-3-1 · Cited by 30
Andō, K., Manabe, R., Kishino, Y., Kusumoto, S., Yamaoka, T., Tanaka, A., Ohmori, T., & Sagara, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032242 · Cited by 29
The origin of brain malignancies at the blood–brain barrier
McDonald, B., Barth, K., & Schmidt, M. H. H. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04934-1 · Cited by 29
Deslypere, G., Gullentops, D., Wauters, E., & Vansteenkiste, J. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918772810 · Cited by 29
Edahiro, R., Kanazu, M., Kurebe, H., Mori, M., Fujimoto, D., Taniguchi, Y., Suzuki, H., Hirano, K., Yokoyama, T., Morita, M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220570 · Cited by 29
Clinical application of whole-genome sequencing of solid tumors for precision oncology
Kim, R., Kim, S., Oh, B. B.-L., Yu, W. S., Kim, C. W., Hur, H., Son, S., Yang, M. J., Cho, D. S., Ha, T., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01288-x · Cited by 28
Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer
Reckamp, K. L. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0046 · Cited by 28
Acquired Resistance in Oncogene-Addicted Non-Small-Cell Lung Cancer
Sini, C., Tuzi, A., Rossi, G., Russo, A., & Pezzuto, A. (2018) · Future Oncology · doi:10.2217/fon-2018-0097 · Cited by 29
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Morcos, P. N., Cleary, Y., Sturm, C., Guerini, E., Abt, M., Donzelli, M., Vazvaei, F., Balas, B. I., Parrott, N. J., & Yu, L. J. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1286 · Cited by 28
Self-citationWei, Z., Ye, X., Yang, X., Huang, G., Li, W., Han, X., Wang, J., Meng, M., Ni, Y., & Li, Q. (2019) · International Journal of Hyperthermia · doi:10.1080/02656736.2019.1642522 · Cited by 30
Digumarthy, S. R., Mendoza, D. P., Lin, J. J., Chen, T., Rooney, M. M., Chin, E. N., Sequist, L. V. D., Lennerz, J. K., Gainor, J. F., & Shaw, A. T. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.10.006 · Cited by 29
Self-citationZhang, E. W., Dagogo‐Jack, I., Kuo, A. H., Rooney, M. M., Shaw, A. T., & Digumarthy, S. R. (2020) · Cancer · doi:10.1002/cncr.33118 · Cited by 28
Self-citationSalting the Soil: Targeting the Microenvironment of Brain Metastases
Srinivasan, E. S., Tan, A. C., Anders, C. K., Pendergast, A. M., Sipkins, D. A., Ashley, D. M., Fecci, P. E., & Khasraw, M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0579 · Cited by 29
Ito, K., Yamanaka, T., Hayashi, H., Hattori, Y., Nishino, K., Kobayashi, H., Oya, Y., Yokoyama, T., Seto, T., Azuma, K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.12.026 · Cited by 28
Oulhen, M., Pawlikowska, P., Tayoun, T., Garonzi, M., Buson, G., Forcato, C., Manaresi, N., Aberlenc, A., Mezquita, L., Lécluse, Y., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00203-1 · Cited by 29
Tsubata, Y., Tanino, R., & Isobe, T. (2021) · Cells · doi:10.3390/cells10113192 · Cited by 31
Metadata
- Authors
- Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 829-838
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2624310346
- Cited by
- 2,527
- References
- 14
- Citations by year
- 2026: 173 · 2025: 216 · 2024: 260 · 2023: 270 · 2022: 306 · 2021: 336 · 2020: 327 · 2019: 276 · 2018: 277 · 2017: 82
- FWCI
- 218.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, public-domain)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Ariad Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Array BioPharma
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Les Laboratories Pierre Fabre
- Clovis Oncology
- G1 Therapeutics
- Eisai
- Genentech
- EMD Serono
- Ignyta
- Loxo Oncology
- Foundation Medicine
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- alectinib, crizotinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, ALK inhibitors, progression-free survival, CNS progression, central nervous system metastasis, objective response rate, overall survival, first-line therapy, targeted therapy, head-to-head comparison
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Adult, Aged, 80 and over, Animals, Antineoplastic Agents, Carbazoles, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Piperidines, Pyrazoles, Pyridines, Central Nervous System Neoplasms, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
